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Purpose: Short stature is a common condition of great concern to
patients and their families. Mostly genetic in origin, the underlying
cause often remains elusive due to clinical and genetic hetero-
geneity.
Methods: We systematically phenotyped 565 patients where
common nongenetic causes of short stature were excluded, selected
200 representative patients for whole-exome sequencing, and
analyzed the identified variants for pathogenicity and the affected
genes regarding their functional relevance for growth.
Results: By standard targeted diagnostic and phenotype assess-
ment, we identified a known disease cause in only 13.6% of the 565
patients. Whole-exome sequencing in 200 patients identified
additional mutations in known short-stature genes in 16.5% of
these patients who manifested only part of the symptomatology. In
15.5% of the 200 patients our findings were of significant clinical
relevance. Heterozygous carriers of recessive skeletal dysplasia
alleles represented 3.5% of the cases.
Conclusion: A combined approach of systematic phenotyping,
targeted genetic testing, and whole-exome sequencing allows the
identification of the underlying cause of short stature in at least 33%
of cases, enabling physicians to improve diagnosis, treatment, and
genetic counseling. Exome sequencing significantly increases the
diagnostic yield and consequently care in patients with short
stature.
Genet Med advance online publication 12 October 2017
Key Words: growth; phenotypic spectrum; short stature; skeletal
dysplasia; whole-exome sequencing
INTRODUCTION
Growth retardation, a common condition leading to reduced
height, is defined as the deviation of an individual's height of
more than two SDs below the mean in the population or the
estimated familial target height.1 The diagnosis is based on
extent and type of growth retardation and other clinical signs
and disorders.1,2 Conditions with growth retardation include
inborn errors of development, which also pose a risk of
various additional health issues like cancer, stroke, and
cardiac defects.3–6 Along with these coexisting conditions,
growth retardation might constitute a substantial emotional
and clinical burden for affected individuals.
Short stature can be caused by nongenetic factors, such as
nutrition, chronic systemic disorders, and emotional or
psychosocial deprivation.7 Most forms of short stature,
however, are based on genetic causes. Turner syndrome,
SHOX defects, mutations in genes affecting the growth
hormone signaling pathway, or rare skeletal dysplasias are
well-known causes.1,8–10 Nevertheless, the cause remains
elusive in about 60–80% of patients, preventing early
treatment of growth retardation and coexisting conditions
as well as adequate genetic counseling.11,12
Human height is a polygenic trait with a heritability of
about 80%.13 Several genome-wide association studies
(GWAS) have identified some 700 common variants explain-
ing 20% of height variation in the normal population and
recently an additional 1.7% have been shown to be caused by
rare and low-frequency coding variants.14,15 These studies
probably explain some cases of short stature whereas recent
studies suggest rare monogenic variants as the more common
underlying cause.16–19 In absence of a specific clinical
phenotype, unbiased genome-wide approaches are necessary
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to uncover such rare variants. We therefore investigated 565
patients with unexplained growth retardation by exhaustive
clinical characterization followed by targeted genetic testing
and exome sequencing in a representative subset of 200
patients.
MATERIALS AND METHDOS
Patients
We enrolled 565 consecutive patients and their families
referred by local medical specialists for evaluation of growth
retardation/short stature (Table 1, Supplementary Figure
S1 online). Of these, 551 patients were of European, 13 of
Asian, and 1 of Arab descent. At time of enrollment, 83%
of the patients were younger than 18 years. 81% presented
with a height of 2 SDs below the age-related mean, whereas
the remaining 19% were 2 SDs below the estimated target
family height. Overall, 20% showed mild learning
disabilities and 21% microcephaly. 30% underwent bone
age evaluation and of those 84% had either delayed or
accelerated bone ages. All 565 patients underwent extensive
prior endocrinological and diagnostic workup to exclude
defects of the growth hormone pathway and organic causes
of their growth deficit. All procedures were in accordance
with the ethical standards of the FAU Erlangen-Nürnberg
and the Helsinki Declaration. Detailed recruitment
information is provided in the Methods section in the
Supplementary Data.
Systematic phenotyping and targeted testing
On enrollment, all 565 patients received extensive genetic
evaluation including syndromic and radiographic assess-
ment by a clinical geneticist according to a standardized
questionnaire. All information was included in a database
based on known phenotype terms, followed by assessment of
published information and discussion with a review board of
experts in clinical genetics and dysmorphology (systematic
phenotyping, Methods section in the Supplementary
Data).20 Targeted genetic testing was applied based on
known disease frequencies and phenotypic characteristics.
Exome sequencing and variant assessment
After exclusion of individuals from the group of 565 patients
in whom our genetic targeted clinical and diagnostic approach
had led to the identification of an underlying genetic cause of
growth retardation, we selected a representative group of 200
patients (Figure 1, Table 1 and Supplementary Figure S1).
These 200 patients showed no statistically significant
difference from the remaining group of patients regarding
age, height distribution, stature type, development, bone age,
and sex (Table 1 and Supplementary Figure S1; selection and
clinical description of the 200 individuals for exome analysis
is provided in the Methods section in the Supplementary
Data).
We performed whole-exome sequencing in this group of
200 patients—100 patients and both parents (trio analysis)
and 100 patients (affected-only analysis)—after enrichment
by SureSelect targeted capturing (Figure 1, Supplementary
Figures S1–S2). Exomes were analyzed with our custom NGS
Variant Analyzer tool, which involves the semiautomatic
selection and data quality inspection of variants followed by
the interpretation in relation to the reported phenotypic
spectrum. The veracity and segregation in the families of
selected variants were confirmed using Sanger sequencing.
All 200 patients were analyzed with respect to 1,000 known
growth related genes derived from OMIM and MedGen
databases (Supplementary Table S2). We considered causal
all variants in known short stature–associated disease genes
when the variant was predicted pathogenic or likely
pathogenic referring to American College of Medical
Genetics and Genomics (ACMG) criteria21 and segregating
with the phenotype in the family (Supplementary Data).
All results were followed by a genotype–phenotype
reevaluation. Detailed information about exome sequencing
Table 1 Clinical characteristics of included patients with
idiopathic short stature
Characteristic All 565 patients 200 Exome patientsa
No. (%) No. (%)
Age group
o 4 y 102 (18) 33 (17)
> 4 y 463 (82) 167 (83)
Small for gestational age 156 (28) 59 (30)
Short stature (SDs)
−2 to –3 270 (48) 99 (50)
−3 to − 4 133 (24) 48 (24)
−4 to − 5 34 (6) 17 (8)
o − 5 19 (3) 9 (4)
Below est. height 109 (19) 27 (14)
Short stature type
Isolated 384 (68) 134 (67)
Syndromic 181 (32) 66 (33)
Head circumference (SDs)
> − 2 448 (79) 140 (70)
−2 to − 3 60 (11) 26 (13)
−3 to − 5 45 (8) 27 (14)
o − 5 12 (2) 7 (3)
IQ
Normal 450 (80) 160 (80)
70–85 115 (20) 40 (20)
Sex
Female 349 (62) 122 (61)
Male 216 (38) 78 (39)
Bone age
Accelerated 16 (3) 11 (5)
Normal 27 (5) 19 (10)
Delayed 125 (22) 68 (34)
Not available 397 (70) 102 (51)
a200 representative patients from the 565 where the prior targeted clinical and
diagnostic approach had not led to the identification of an underlying cause.
These patients showed no statistical difference for each single or combined char-
acteristic.
Genetic evaluation of patients with short stature | HAUER et al ORIGINAL RESEARCH ARTICLE
GENETICS in MEDICINE | Volume 20 | Number 6 | June 2018 631
and interpretation of variants in known short-stature genes is
provided in the Methods section in the Supplementary Data.
Data availability
Data for various analyses have been mentioned throughout
the text and derived data supporting the findings of this study
are available from the corresponding author upon request.
Any other data associated with this study are available in the
Supplementary Data. Additional methods are described in
the Supplementary Data.
RESULTS
Diagnostic yield of common and recognizable phenotypes
in 565 individuals
We could establish a diagnosis after systematic phenotyping
in 13.6% of patients including disorders due to variants in
10 genes, imprinting defects, large chromosomal aberrations,
and 24 distinct copy-number variants (Supplementary
Table 1). Copy-number variants ranging in size from 0.1
to 14.2 Mb were the most common cause of nonspecific
syndromic short stature, identified in 6.9% of the patients. A
syndromic form of short stature was suspected in 181
patients and confirmed in 26 of them (4.6% of the
565 patients), mostly SHOX-related short stature and
Silver–Russell syndrome. Turner syndrome or Turner
syndrome variants were found in 1.6% of the patients and
mutations in genes associated with skeletal dysplasia in
0.5%. No diagnosis could be established in 491 (86.4%) of
the patients.
Diagnostic yield of exome sequencing in 200 individuals
To confirm the power of family-based exome sequencing in
providing a diagnosis in individuals with growth retardation
we selected a representative group of 200 families of the
remaining patients with unexplained growth retardation
(Figure 1, Table 1, and Supplementary Figure 1). We
considered genes associated with growth phenotypes
according to OMIM and MedGen databases and in these
confirmed variants with regard to segregation and the specific
patient’s phenotype. Thereby, we identified 38 variants
affecting 26 genes in 33 of 200 exome patients (16.5%
of the exome group; Table 2, Supplementary Figures
S3–S27 and Supplementary Tables S2–S4). Of the 38
variants, 27 (71%) were missense, 5 (13%) frameshift,
4 (11%) nonsense, and 2 (5%) canonical splice-site variants.
Twenty-nine of the 38 variants were not reported in
the Exome Aggregation Consortium database, and nine
were rare, with a maximum frequency of 2 × 10 − 4.
Following the ACMG guidelines,21 16 of the identified 38
variants (42%) were classified as likely pathogenic and
the remaining 22 (58%) were defined as pathogenic
variants (Materials and Methods section, Table 2, and
Supplementary Table S4). The median height of these 33
patients was 2.7 SDs below the average height in the
population, 21% showed microcephaly, and 41% were
classified as syndromic (Supplementary Figure S1 and
Supplementary Table S3). Modes of inheritance were
autosomal dominant (65%), autosomal recessive (19%),
and X-linked recessive (15%) (Table 2, Supplementary
Tables S3–S4). Pathway analyses of the affected proteins
revealed that 58% of them are involved in the main
functional categories of cartilage formation, chromatin
modification, and Ras-MAPK signaling (Table 3).
We further wanted to know whether the selection of specific
phenotypes or a combination of phenotypic features might
reveal a higher diagnostic yield. A support vector machine
approach resulted in 85.5% probability that it is not currently
565 individuals with
unexplained short stature / growth reduction
565 patients diagnostic workup
of common and recognizable causes
Diagnostic yield
13.6%
Whole-exome sequencing of 200
representative individuals without known cause
Mutations in known short stature genes
Additional diagnostic yield
16.5%
Combined diagnostic yield
33%
Diagnosis & intervention
Genotype–phenotype interpretation
Genetic counseling
Symptomatic treatment
Targeted treatment
Systematic phenotyping
Clinical phenotype
Growth pattern
Dysmorphic features
Radiographic evaluation
Psychomotor development
Mode of inheritance
Pedigree
Figure 1 Flowchart gene discovery approach. We built a study group
of 565 individuals with short stature or growth retardation (Table 1).
Systematic phenotyping and targeted diagnostic testing of common and
recognizable causes in all 565 patients led to a diagnostic yield of 13.6%
(Supplementary Table 1). Detailed information about the systematic
phenotyping is provided in the Methods section in the Supplementary
Data. For 200 representative individuals where no underlying cause could
be determined (Table 1), we performed whole-exome sequencing, which
increased the diagnostic yield by 17% up to 33% by the identification of
mutations in known short stature–associated genes (Table 2,
Supplementary Tables 3–4). Genotype–phenotype re-evaluation
confirmed that these patients present with only part of the characteristic
symptomatology. The additional diagnostic yield already had direct effects
in preventive measures, symptomatic and targeted treatment in
15.5% of the 200 exome-sequenced patients (Table 4 and
Supplementary Table S6).
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possible to accurately predict the presence of a pathogenic
mutation based on one or a combination of clinical subgroups
(height, occipitofrontal circumference, intellectual disability,
syndromic versus isolated phenotype, prenatal growth
retardation, and accelerated/decelerated bone age) (Methods
section in the Supplementary Data).
Overall, considering only genes previously associated with
growth retardation, the diagnostic yield of 13.6% achieved
with systematic phenotyping and targeted testing was raised
to 33% by additional exome sequencing (Figure 1). The
most commonly mutated known short stature–associated
genes identified were ACAN (2.5%), NPR2 (1.5%), KDM6A
(1%), and COL2A1 (1%) (Table 2 and Supplementary Tables
S3–S4).
Expansion of the phenotypic spectrum by exome
sequencing
Some of the mutations identified by exome sequencing are
located in genes known to be associated with syndromic
intellectual disability or skeletal dysplasia (Table 2 and
Supplementary Tables S3–S5). One patient with a novel
pathogenic KRAS missense mutation presented with
proportionate short stature and learning disability illustrating
the mild end of the Noonan syndrome spectrum disorders.22
Two patients with KDM6A mutations demonstrated the
phenotypic variability of Kabuki syndrome.23,24 Neither
showed any signs of developmental delay but they presented
with part of the characteristic facial gestalt. Short stature is
also an essential symptom of many skeletal dysplasias.9 We
found mutations in FGFR3, COL2A1, and SLC26A2 in four
patients presenting with no obvious specific skeletal
involvement at initial clinical evaluation but consistent with
the mild end of the spectrum of these entities upon re-
evaluation. Finally, we identified a previously unreported
likely pathogenic hemizygous missense mutation in the
calcium/calmodulin-dependent serine protein kinase gene
(CASK) in a male patient with mild short stature and
microcephaly but no intellectual disability. Loss-of-function
CASK mutations underlie several forms of X-linked intellectual
disability syndromes and patients are reported to present with
short stature.25
Carriers of recessive skeletal dysplasia mutations present
with idiopathic short stature
In 3.5% of the 200 exome patients we identified heterozygous
mutations in two genes (ACAN, NPR2) previously reported to
cause the autosomal-recessive skeletal dysplasias spondyloe-
pimetaphyseal dysplasia and acromesomelic dysplasia, respec-
tively (Table 2, Supplementary Tables S3–S5).9,26
Heterozygous carriers consistently show idiopathic short
stature without dysmorphic findings.26–30 We found
heterozygous mutations in ACAN in five and NPR2 in three
patients who were not previously suspected to be carriers. The
height of these patients ranged between − 2.0 and − 4.7 SDs
(Supplementary Table S3). One patient carried both a variant
in NPR2 and a variant in ACAN. This could indicate a
blended phenotype as previously reported.31
Additional relevance of exome sequencing results for
clinical management
Besides the increased diagnostic yield by exome sequencing in
the 200 patients with idiopathic short stature, results with
possible impact on treatment or additional preventive
measurements occurred in 31 families (15.5% of 200 exome
individuals, Table 4 and Supplementary Table S6). This led
to preventive measures for osteoarthritis (ACAN, CUL7,
MATN3) and neoplasias (NF1, PTPN11, TRIM37), as well as
orthopedic support and regular developmental evaluation in
affected individuals from 23 families (11.5%). Symptomatic
treatment or screening for associated malformations (KAT6B,
KRAS, MAP2K1, PTPN11), hearing loss (COL2A1, FLNB), or
the risk for chronic kidney disease (IFT140, CLCN5) was
recommended in nine families (4.5%). A treatment with
recombinant growth hormone or IGF1 has been shown to be
beneficial especially in the individuals with defects of the
growth hormone pathway.32–34 We identified mutations
affecting genes of this pathway (GHSR, IGF1R) allowing
specific treatment in three families (1.5%). Interestingly, these
have been missed by endocrine testing, but were confirmed by
Table 3 Diagnostic yield of exome sequencing in 200 patients
Main functional categorya No. of genes Identified genes (no. of patients affected)
Cartilage formation 6 ACAN (5), COL2A1 (2), FGFR3 (1), IHH (1), MATN3 (1), SLC26A2 (1)
Chromatin modification 5 KDM6A (2), ANKRD11 (1), HDAC6 (1), KAT6B (1), TRIM37 (1)
Ras-MAPK pathway 4 KRAS (1), MAP2K1 (1), NF1 (1), PTPN11 (1)
Growth hormone–related pathway 2 GHSR (1), IGF1R (1)
Regulation of cytoskeleton 2 FGD1 (1), FLNB (1)
cAMP signaling pathway 2 PDE3A (1), PDE4D (1)
Centrosome/cilia formation 2 CUL7 (1), IFT140 (1)
mTOR signaling pathway 1 NPR2 (3)
Transcription regulation 1 CASK (1)
Renal regulation 1 CLCN5 (1)
cAMP, cyclic adenosine monophosphate; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin.
aFrom DAVID functional annotation, OMIM, and KEGG.
Genetic evaluation of patients with short stature | HAUER et al ORIGINAL RESEARCH ARTICLE
GENETICS in MEDICINE | Volume 20 | Number 6 | June 2018 635
growth hormone stimulation tests and therefore considered at
least to contribute in part to the patient’s growth phenotype.
Also immediately relevant was the identification of a PDE3A
mutation in one girl. Activating mutations in PDE3A led to
hypertension and brachydactyly syndrome (MIM 123805)
with the development of life-threatening hypertension later in
life.35 A targeted treatment with phosphodiesterase inhibitors
is indicated due to its potentially significant impact on life
expectancy.36 Finally, knowledge about the inheritance
pattern will aid evaluation of the recurrence risk and improve
genetic counseling of families.
DISCUSSION
Even though the heritability of short stature is considered
high, the large number of genes implicated and the
nonspecific clinical phenotype have led to poor yield of
diagnostic genetic testing.13,16,18,19,37–39 To demonstrate the
diagnostic outcome we enrolled 565 carefully characterized
patients with short stature and their families and established
an interdisciplinary systematic phenotyping with additional
targeted gene testing (Figure 1). This led to a diagnostic yield
of 13.6% including copy-number variants, chromosomal
aberrations, and monogenic causes (Supplementary Table
S1). We next performed unbiased exome sequencing in 200
representative patients with short stature of unknown
origin (Table 1 and Supplementary Figure S1). The variant
evaluation and classification in accordance with the ACMG
guidlines21 led to the identification of mutations in known
short stature–associated genes in 33 affected individuals
(16.5%) (Table 2, Supplementary Tables S3–S5). In a
previous smaller study of 14 highly selected patients a
diagnostic yield of 36% was reported,16 which might be
explained by the study’s strict inclusion criteria and smaller
sample size. Genotype–phenotype re-evaluation confirmed
that the individuals from our exome study were lacking
most of the characteristic features of the entities, indicating
that current descriptions are biased and that the phenotypic
spectrum needs to be expanded. This is especially true
for genes associated with syndromic forms of short stature
and intellectual disability as well as skeletal dysplasias.
There are parallels to the field of intellectual disability, also
plagued by high genetic heterogeneity and unspecific clinical
presentation, where both a similar mutation yield and
inheritance modes were reported.40 However, in this study
clinical subgrouping did not reveal any correlation between a
specific phenotypic feature or combination of them and the
probability to identify a mutation, thus supporting an
unbiased approach such as exome analysis for all patients
with idiopathic short stature.
One remarkable aspect was the detected frequency of
heterozygous mutations in genes previously implicated in
autosomal-recessive skeletal dysplasias (ACAN, NPR2),
confirming a dosage effect of cartilage matrix proteins
in growth development.26,27,29,30 In our exome study,
ACAN was the most commonly mutated known short
stature–associated gene with a frequency of 2.5%
(Supplementary Table S2), whereas the previously
reported most common single-gene defect affects SHOX
with a frequency of 2.4%.8
An important aspect of the clinical application of whole-
exome sequencing in short stature concerns prognosis,
prevention, and treatment (Table 4 and Supplementary
Table S6). In 11.5% of the families, the identification of the
molecular cause of the disease by exome sequencing
prompted further preventive action. The girl diagnosed
with a mutation in PDE3A might benefit from current
targeted treatment with phosphodiesterase inhibitors to
reduce her high risk of life-threatening coronary artery
disease and essential hypertension after puberty.35 Also
1.5% of the affected individuals became eligible for targeted
treatment for growth retardation itself. Finally, 5% of the
patients could benefit from treatment or screening for
associated malformations. None of these clinical applica-
tions were considered prior to genetic diagnosis by exome
sequencing, but they have now been applied to the
patients’ care.
Table 4 Intervention in affected 200 exome individuals with mutations in known short-stature genes
Type Symptom Genesa
Preventive measures Osteoarthritis ACAN, CUL7, MATN3
Hearing loss COL2A1
Orthopedic symptoms COL2A1, FGFR3, IHH, SLC26A2, HDAC6, FLNB
Developmental issues KDM6A, ANKRD11, PDE4D, CASK, FGD1, PTPN11, NF1
Bleeding diathesis PTPN11
Neoplasia TRIM37, PTPN11, NF1
Symptomatic treatment Hearing loss COL2A1, FLNB
Multiple malformations KAT6B, KRAS, MAP2K1, PTPN11
Chronic kidney disease IFT140, CLCN5
Targeted treatment Growth hormone signaling pathway defects GHSR, IGF1R, PTPN11
Severe hypertension PDE3A
aInformation derived from GeneReviews and other publications (Supplementary Table S5).
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In conclusion, we demonstrated that systematic phenotyp-
ing combined with targeted genetic testing and exome
sequencing increases the diagnostic yield in short stature up
to 33% with concomitant improvement in treatment and
prevention. As height has a proposed heritability of about
80%, and as the ongoing rate of discovery in other entities
suggests,40 we expect that future identification of potential
candidate genes, as well as their analysis in additional patients,
will increase the diagnostic yield.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
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